Use of intra-aortic balloon pump
Ask the expert
The report presents a summary of reimbursement situation for the use of intra-aortic balloon pump (IABP) in cardiogenic shock in Europe.
The following scenarios will be considered:
- Use of IABP for treatment of cardiogenic shock in unstable angina or acute myocardial infarction;
- Use of IABP in high-risk PCI for unstable angina or acute myocardial infarction.
The only reimbursement within public / statutory health insurance systems is considered. The results will be provided for hospital settings.
Report includes essential information about reimbursement and national funding, including:
- Brief overview of reimbursement system for medical devices
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions in indications or scenarios for use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- England (UK)
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Manufacturers of intra-aortic balloon pump (myocardial infarction and unstable angina, complicated by cardiogenic shock) include:
- Abiomed (iPulse)
- Insightra Medical (ULTRA 7FR)
- Getinge (Cardiosave, CS)
- Senko Medical (Corart)
- Teleflex (AutoCAT2, AC3 Optimus)
- Tokai Medical Products (7Fr-TAU)
- Zeon Medical (Xemex)
Table of content is not available at the moment. Report is still ongoing.
The Agency for Health Technology Assessment of Andalusia Autonomous Community in Spain (AETSA) systematically evaluates healthcare technologies and provides decision-makers with critically review information about their efficacy, safety, and effectiveness. Currently, the AETSA is working on assessments of laser-induced heat therapy in epilepsy surgery, stereotactic radiation therapy for the treatment of refractory ventricular tachycardia, implantable Holter monitor with ILink Online technology for prolonged cardiac monitoring, and other topics.Read more
The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 6462 of April 21, 2021, Tuscany Regional Healthcare has published assessments of six medical devices of various therapeutic areas, including devices for the treatment of vaginal prolapse, cardiovascular conditions, an implant for vocal cord rehabilitation, and a cerebral embolic protective device.Read more
On April 09, 2021, the Swedish Medical Technologies Product (MTP) Council decided to add more technologies to the ongoing evaluation for self-monitoring of atrial fibrillation within the Orderly introduction framework, initiated in December 2020. MTP Council commissioned the Dental and Pharmaceutical Benefits Agency (TLV) to perform a health-economic evaluation of five products (Coala, KardiaMobile, CardioMem CM 100 XT, PhysioMem PM 100, Zenicor). MTP Council will then make recommendations to the regions on whether to adopt these technologies or not.Read more
On February 18, 2021, the updated List of Reimbursable Products and Services (LPPR) was published. It contains new devices included in the LPPR list in January-February 2021, as well as other modifications made during this period. The newly-included devices belong to the cardiovascular (TAVI), ENT (cochlear and brainstem implants), and diagnostic imaging (FFR) technology groups.Read more
In March 2021, the new mini-HTAs of five technologies were initiated in Norway: Harpoon - transapical neochordae device, tricuspidal clip, portable hand-held spirometry, CGM device and insulin pump, and portable spirometry device. The final mini-method assessment will be published in the National Database for Mini-HTA.Read more